US Bancorp
FATE icon

US Bancorp’s Fate Therapeutics FATE Stock Holding History

US Bancorp’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-437
Closed -$721 – 4257
2024
Q4 		$721 Sell
437
-151
-26% -$380 ﹤0.01% 3997
2024
Q3 		$2.06K Sell
588
-987
-63% -$3.84K ﹤0.01% 3778
2024
Q2 		$5.17K Buy
+1,575
New +$6.89K ﹤0.01% 3504
2024
Q1 		– Sell
-7,991
Closed -$29.9K – 4015
2023
Q4 		$29.9K Buy
7,991
+5,586
+232% +$13.2K ﹤0.01% 2894
2023
Q3 		$5.1K Sell
2,405
-1,922
-44% -$6.37K ﹤0.01% 3427
2023
Q2 		$20.6K Buy
4,327
+2,086
+93% +$11.5K ﹤0.01% 2961
2023
Q1 		$12.8K Buy
2,241
+935
+72% +$5.64K ﹤0.01% 3190
2022
Q4 		$13.2K Sell
1,306
-12,424
-90% -$233K ﹤0.01% 3205
2022
Q3 		$307K Buy
13,730
+13,362
+3,631% +$386K ﹤0.01% 1624
2022
Q2 		$9K Buy
368
+68
+23% +$1.88K ﹤0.01% 3388
2022
Q1 		$11K Sell
300
-180
-38% -$6.97K ﹤0.01% 3337
2021
Q4 		$28K Sell
480
-213
-31% -$12.1K ﹤0.01% 2932
2021
Q3 		$41K Sell
693
-97
-12% -$7.61K ﹤0.01% 2732
2021
Q2 		$68K Buy
790
+268
+51% +$21.6K ﹤0.01% 2503
2021
Q1 		$43K Buy
522
+407
+354% +$39K ﹤0.01% 2650
2020
Q4 		$11K Buy
115
+98
+576% +$6.09K ﹤0.01% 3142
2020
Q3 		$1K Hold
17
– – ﹤0.01% 3575
2020
Q2 		$1K Buy
+17
New +$507 ﹤0.01% 3592
2018
Q4 		– Sell
-922
Closed -$15K – 3615
2018
Q3 		$15K Buy
922
+62
+7% +$733 ﹤0.01% 3002
2018
Q2 		$10K Buy
+860
New +$9.47K ﹤0.01% 3126

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

US Bancorp's FATE Position: Q1 2025 in Review

US Bancorp sold out of Fate Therapeutics (FATE) in Q1 2025, closing a stake of 437 shares — an estimated $721 sold.

US Bancorp first reported a position in FATE in Q2 2018 and held it in 20 quarters. The position peaked at $307K in Q3 2022. 132 funds tracked by Wall St. Rank hold FATE as of Q1 2025.

  • US Bancorp reported no remaining Fate Therapeutics position as of Q1 2025 after selling out during the quarter.
  • US Bancorp sold 437 Fate Therapeutics shares in Q1 2025, an estimated $721.
  • US Bancorp first reported a position in Fate Therapeutics in Q2 2018 and held it in 20 quarters.
  • US Bancorp's Fate Therapeutics position peaked at $307K in Q3 2022.
  • 132 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2025.

Based on US Bancorp's 13F filing for Q1 2025, filed 8 May 2025.